285 related articles for article (PubMed ID: 28495793)
21. Targeting the Ataxia Telangiectasia Mutated-null phenotype in chronic lymphocytic leukemia with pro-oxidants.
Agathanggelou A; Weston VJ; Perry T; Davies NJ; Skowronska A; Payne DT; Fossey JS; Oldreive CE; Wei W; Pratt G; Parry H; Oscier D; Coles SJ; Hole PS; Darley RL; McMahon M; Hayes JD; Moss P; Stewart GS; Taylor AM; Stankovic T
Haematologica; 2015 Aug; 100(8):1076-85. PubMed ID: 25840602
[TBL] [Abstract][Full Text] [Related]
22. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.
Kojima K; Konopleva M; McQueen T; O'Brien S; Plunkett W; Andreeff M
Blood; 2006 Aug; 108(3):993-1000. PubMed ID: 16543464
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
24. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.
Voltan R; Rimondi E; Melloni E; Rigolin GM; Casciano F; Arcidiacono MV; Celeghini C; Cuneo A; Zauli G; Secchiero P
Oncotarget; 2016 Oct; 7(43):70623-70638. PubMed ID: 27661115
[TBL] [Abstract][Full Text] [Related]
25. ATM-dependent downregulation of USP7/HAUSP by PPM1G activates p53 response to DNA damage.
Khoronenkova SV; Dianova II; Ternette N; Kessler BM; Parsons JL; Dianov GL
Mol Cell; 2012 Mar; 45(6):801-13. PubMed ID: 22361354
[TBL] [Abstract][Full Text] [Related]
26. NOD/SCID IL2Rγ-null mouse xenograft model of human p53-mutated chronic lymphocytic leukemia and ATM-mutated mantle cell lymphoma using permanent cell lines.
Verner J; Trbusek M; Chovancova J; Jaskova Z; Moulis M; Folber F; Halouzka R; Mayer J; Pospisilova S; Doubek M
Leuk Lymphoma; 2015; 56(11):3198-206. PubMed ID: 25827173
[TBL] [Abstract][Full Text] [Related]
27. The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53.
Thomas A; Perry T; Berhane S; Oldreive C; Zlatanou A; Williams LR; Weston VJ; Stankovic T; Kearns P; Pors K; Grand RJ; Stewart GS
Oncogene; 2015 Jun; 34(25):3336-48. PubMed ID: 25132271
[TBL] [Abstract][Full Text] [Related]
28. Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.
Alonso R; López-Guerra M; Upshaw R; Bantia S; Smal C; Bontemps F; Manz C; Mehrling T; Villamor N; Campo E; Montserrat E; Colomer D
Blood; 2009 Aug; 114(8):1563-75. PubMed ID: 19541822
[TBL] [Abstract][Full Text] [Related]
29. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic lymphocytic leukemia.
Kaufman KL; Jenkins Y; Alomari M; Mirzaei M; Best OG; Pascovici D; Mactier S; Mulligan SP; Haynes PA; Christopherson RI
Oncotarget; 2015 Dec; 6(38):40981-97. PubMed ID: 26556860
[TBL] [Abstract][Full Text] [Related]
30. USP7 controls Chk1 protein stability by direct deubiquitination.
Alonso-de Vega I; Martín Y; Smits VA
Cell Cycle; 2014; 13(24):3921-6. PubMed ID: 25483066
[TBL] [Abstract][Full Text] [Related]
31. Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia.
te Raa GD; Malcikova J; Pospisilova S; Trbusek M; Mraz M; Garff-Tavernier ML; Merle-Béral H; Lin K; Pettitt AR; Merkel O; Stankovic T; van Oers MH; Eldering E; Stilgenbauer S; Zenz T; Kater AP;
Leuk Lymphoma; 2013 Aug; 54(8):1849-53. PubMed ID: 23614766
[TBL] [Abstract][Full Text] [Related]
32. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
Shi Q; Shen LY; Dong B; Fu H; Kang XZ; Yang YB; Dai L; Yan WP; Xiong HC; Liang Z; Chen KN
Cancer Lett; 2018 Sep; 432():56-68. PubMed ID: 29890208
[TBL] [Abstract][Full Text] [Related]
33. Ability to downregulate the level of cyclin-dependent kinase inhibitor p27
Raskova Kafkova L; Navrkalova V; Jarosova M; Loja T; Chovancova J; Kucerova J; Kriegova E; Prochazka V; Novak Z; Simkova D; Pospisilova S; Divoky V
Leuk Lymphoma; 2017 Jan; 58(1):199-203. PubMed ID: 27268868
[No Abstract] [Full Text] [Related]
34. The impact of SF3B1 mutations in CLL on the DNA-damage response.
Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
[TBL] [Abstract][Full Text] [Related]
35. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.
Athanasakis E; Melloni E; Rigolin GM; Agnoletto C; Voltan R; Vozzi D; Piscianz E; Segat L; Dal Monego S; Cuneo A; Secchiero P; Zauli G
Oncotarget; 2014 Dec; 5(24):12635-45. PubMed ID: 25587027
[TBL] [Abstract][Full Text] [Related]
36. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for fludarabine refractory disease.
Best OG; Che Y; Singh N; Forsyth C; Christopherson RI; Mulligan SP
Leuk Lymphoma; 2012 Jul; 53(7):1367-75. PubMed ID: 22149137
[TBL] [Abstract][Full Text] [Related]
37. FAM188B enhances cell survival via interaction with USP7.
Choi ES; Lee H; Sung JY; Lee CH; Jang H; Kim KT; Kim YN; Kim HP; Goh SH
Cell Death Dis; 2018 May; 9(6):633. PubMed ID: 29795372
[TBL] [Abstract][Full Text] [Related]
38. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab.
Sebejova L; Borsky M; Jaskova Z; Potesil D; Navrkalova V; Malcikova J; Sramek M; Doubek M; Loja T; Pospisilova S; Mayer J; Trbusek M
Exp Hematol; 2014 Oct; 42(10):867-74.e1. PubMed ID: 24970561
[TBL] [Abstract][Full Text] [Related]
39. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.
Zenz T; Benner A; Döhner H; Stilgenbauer S
Cell Cycle; 2008 Dec; 7(24):3810-4. PubMed ID: 19098429
[TBL] [Abstract][Full Text] [Related]
40. Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals.
Xie H; Li C; Dang Q; Chang LS; Li L
Oncotarget; 2016 Jan; 7(2):1341-53. PubMed ID: 26625310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]